BRIEF-Fibrogen Exercises Exclusive License Option For Hifibio'S CCR8 Program
* FIBROGEN EXERCISES EXCLUSIVE LICENSE OPTION FOR HIFIBIO'S CCR8 PROGRAM
* FIBROGEN INC (FGEN) - HIFIBIO TO RECEIVE
* FIBROGEN INC (FGEN) - HIFIBIO WILL ALSO BE ELIGIBLE TO RECEIVE ROYALTIES BASED UPON NET SALES.
* FIBROGEN INC (FGEN) - DEVELOPMENT CANDIDATE IS EXPECTED TO ENTER CLINICAL DEVELOPMENT IN 2023.
* FIBROGEN INC (FGEN) - WILL HAVE SOLE RIGHT TO DEVELOP ALL PRODUCTS IN CCR8 PROGRAM WORLDWIDE Source text for Eikon: Further company coverage: